|
|
 | | | |
- close
- close
- close
- close
Dynavax Technologies (DVAX) |
StreetInsider.com
May 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Dynavax+Technologies+Corp+%28DVAX%29+Reports+In-Line+Q1+EPS/8308550.html for the full story.
StreetInsider.com
Apr 30
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Dynavax+%28DVAX%29+Taps+Glaxo%27s+%28GSK%29+Eddie+Gray+as+CEO/8288985.html for the full story.
TheStreet.com
Mar 13
Comment
WINDERMERE, Fla. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.
Stocks that are making large moves like these are favorites among short-term traders...
StreetInsider.com
Mar 1
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Dynavax+Technologies+Corp+%28DVAX%29+Reports+Q4+Loss+of+%240.11/8148129.html for the full story.
Benzinga
Feb 25
Comment
Plug Power (NASDAQ: PLUG) shares dipped 8.68% to touch a new 52-week low of $0.1189. Plug Power's trailing-twelve-month ROE is -103.98%.
Dynavax Technologies (NASDAQ: DVAX) shares dropped 36.70% to touch a new 52-week low of $1.88. The US FDA...
StreetInsider.com
Feb 25
Comment
Affymax, Inc. (NASDAQ: AFFY) 86% LOWER; the company and partner Takeda recalled all lots of OMONTYS Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can...
FierceBiotech
Feb 25
Comment
The FDA has rejected Dynavax Technologies' hepatitis B vaccine Heplisav, fretting over the same safety issues that spurred an expert committee to vote against an approval last fall. In a statement, Dynavax noted that regulators want to see further...
Benzinga
Feb 25
Comment
In a report published Monday, MLV & Co. downgraded its rating on Dynavax Technologies Corporation (NASDAQ: DVAX) from Buy to Hold.
MLV noted, “After months of DVAX stock volatility and speculation as to what the immediate future of Dynavax's...
TheStreet.com
Feb 25
Comment
BERKELEY, Calif. (TheStreet) -- The U.S. Food and Drug Administration rejected Dynavax's hepatitis B vaccine Heplisav, citing the need for additional safety data in healthy adults.
Dynavax shares fell 37% to $1.88 in Monday's pre-market...
TheStreet.com
Feb 13
Comment
NEW YORK (TheStreet) -- My first column for TheStreet last September and was titled "Dynavax: The BioRunUp Trade Into An FDA Panel." Run-up traders experienced only mediocre gains. Dynavax shares at $3-plus only rose to $5 before pulling...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
Dynavax Technologies Corporation (NASDAQ:DVAX) is a clinical-stage biopharmaceutical company that discovers and develops products that prevent and treat infectious and inflammatory diseases.[1] Dynavax partners with major pharmaceutical companies including GlaxoSmithKline (NYSE:GSK), AstraZeneca (NYSE:AZN), and Novartis (NYSE:NVS) in order to fund and support discovery and development programs.
References
| |||||||
